Return to the catalog
Selank
NewIn Stock10mg vial

Selank

Tuftsin-based peptide studied for stress responses, calming signals, and immune activity.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 650.00
5+ vials — save 20%R 520.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

Selank is a synthetic analogue of an active fragment of tuftsin, an immune-system peptide. It is studied primarily for its anxiolytic (anxiety-reducing) effects, with research examining its ability to modulate brain chemistry and support stress management without producing sedation. Researchers also investigate Selank for cognitive support and mood regulation, with published studies exploring its effects on memory consolidation, mental stability, and emotional balance in laboratory models.

Why researchers reach for Selank

Anxiolytic-like data

Referenced in rodent anxiety and stress-response models.

Enkephalin stabilization

Reduces breakdown of endogenous enkephalins in vitro.

Immunomodulation

Alters cytokine expression in preclinical work.

Key features

  • ≥99% HPLC purity
  • Tuftsin-derived heptapeptide
  • Mass-spec verified
  • Cold-chain dispatch

How it works

GABA system

Modulates GABA receptor expression in rodent brain regions.

Enkephalin pathway

Inhibits enkephalin-degrading enzymes.

Cytokine signaling

Adjusts IL-6 and interferon expression in animal models.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 5 mg/mL (5000 mcg/mL)
Reported research range250–750 mcg/dayReference only

Tracking this compound? Registered researchers can log active Selank protocols in their private Research Log.

Timing in research protocols

Intranasal, two to three times across waking hours, over multi-week courses.

  • Approved Russian product labelling reports 92.8% intranasal bioavailability, plasma appearance within 30 seconds and clearance in roughly 5 minutes.
  • That very short half-life is why trials (Zozulya 2008; Medvedev 2015) use repeated daily intranasal dosing rather than a single dose.
  • Reported frequency in the primary literature is two to three times daily, spread across waking hours.
  • No morning-versus-evening rationale is established beyond covering the waking day; courses run for weeks.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
Thr-Lys-Pro-Arg-Pro-Gly-Pro
Molecular weight
751.9 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
10 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on Selank. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#anxiolytic#immunomodulator#nootropic

Cart (0)

Your cart is empty